Publications

Spencer C and Fatemi S. Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Practice and Research Clinical Endocrinology & Metabolism. 27(5): 701-12, 2013.  PMID: 24094640

Spencer CA, LoPresti JS and Fatemi S.. How Sensitive (Second-Generation) Thyroglobulin (Tg) Measurement is Changing Paradigms for Monitoring Patients with Differentiated Thyroid Cancer (DTC), in the Absence or Presence of Tg Autoantibodies (TgAb). Current Opinion in Endocrinology and Diabetes 21(5):394-404, 2014.  

PMID: 25122493 PMCID: PMC4154792

Spencer CA. Clinical Review: Clinical Utility of Thyroglobulin antibody (TgAb) measurements for patients with Differentiated Thyroid Cancers (DTC). JCEM 96(12): 3615-27, 2011. 

PMID: 21917876

Spencer CA, Petrovic I, Fatemi S and LoPresti JS. Serum Thyroglobulin (Tg) Monitoring of Patients with Differentiated Thyroid Cancer using Sensitive (Second-Generation) Immunometric assays (Tg2GIMA) can be disrupted by False-Negative and False-Positive Serum Thyroglobulin Autoantibody (TgAb). JCEM 99(12):4589, 2014. PMID: 25226290 PMCID: PMC4297889

Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer.

JCEM 96(5): 1283-91, 2011.  PMID: 21325460

USC ENDOCRINE SERVICES LABORATORY
126 W. Del Mar Blvd 
Pasadena, CA 91105-2508
Phone: (855) 224-7111
Fax: (855) 224-7123

Email: endolab@usc.edu

The USC Endocrine Services Laboratory is licensed by the State of California, Department of Health Services, and accredited by the College of American Pathologists, and certified by Medicare according to the provisions of the U.S. Department of Health and Human Services Clinical Laboratory Improvement Act of 1988.

1975 - 2020. All Rights Reserved.